Skip to main content

Table 2 Outcomes in the overall and matched cohorts and results of propensity score matching analysis

From: Antithrombin use and mortality in patients with stage IV solid tumor-associated disseminated intravascular coagulation: a nationwide observational study in Japan

Outcomes

Unmatched cohort

Matched cohort

Hazard ratios, odds ratios or differences (95% CI)

P-value

Control

(n = 24,377)

AT

(n = 922)

Control

(n = 3676)

AT

(n = 919)

28-day mortality, n (%)

7545 (31.0%)

278 (30.2%)

1061 (28.9%)

278 (30.3%)

1.08 (0.95 to 1.23)

0.37

Organ failure score, mean (SD)

1.46 (0.71)

1.78 (0.93)

1.80 (0.90)

1.78 (0.93)

0.04 (−0.05 to 0.12)

0.40

Critical bleeding, n (%)

1338 (5.5%)

56 (6.1%)

254 (6.9%)

56 (6.1%)

0.86 (0.60 to 1.24)

0.42

  1. AT Antithrombin, CI Confidence intervals, SD Standard deviation